Form 4: Alzamend Neuro Director Ault Adjusts Holdings

Alzamend Neuro Director Milton C. Ault III reported multiple transactions in company stock, including conversions of preferred shares and open market sales, impacting his beneficial ownership.

Summary

• Milton C. Ault III, a Director and 10% Owner of Alzamend Neuro, Inc., reported several transactions in the company's securities.
• On October 3, 2025, 100,000 shares of common stock were acquired through the conversion of Series B convertible preferred stock at a price of $2.32 per share.
• On October 6, 2025, 82,033 shares of common stock were sold in open market transactions at a volume weighted average price of $2.4535 per share.
• On October 7, 2025, another 100,000 shares of common stock were acquired through the conversion of Series B convertible preferred stock at a price of $2.32 per share.
• Also on October 7, 2025, 57,379 shares of common stock were sold in open market transactions at a volume weighted average price of $2.4914 per share.
• Following these transactions, beneficial ownership through Ault Lending, LLC, stands at 68,848 shares of common stock.
• Additional beneficial ownership includes 1,843 shares held directly, 11,068 shares indirectly through Ault Life Sciences, Inc., and 61 shares indirectly through Ault Life Sciences Fund, LLC.
• Derivative holdings include Series B Convertible Preferred Stock (143.2447 shares) and Common Stock Purchase Warrants (totaling 23,334 shares underlying) held indirectly by Ault Lending, LLC.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While there were open market sales, the overall beneficial ownership of common stock increased due to significant conversions of preferred stock, indicating a strategic shift towards common equity by a key insider.

Positives

• The conversion of 464 shares of Series B Convertible Preferred Stock into 200,000 shares of common stock indicates a shift towards more liquid equity holdings.
• Despite open market sales, the net effect of the reported transactions resulted in an increase of 60,588 shares in common stock beneficial ownership through Ault Lending, LLC.

Negatives

• Milton C. Ault III sold a total of 139,412 shares of common stock in open market transactions, reducing his direct exposure to the company's common stock.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Milton C. Ault III is deemed to have voting and investment power over securities held by Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC, which are entities through which he indirectly holds beneficial ownership.

Stakeholder Impact

• Shareholders: Changes in insider ownership can influence investor perception and confidence in the company's stock.

Key Dates

Recommendation

The filing reports mixed insider transactions, with significant conversions of preferred stock into common stock alongside open market sales. While the net effect is an increase in common stock beneficial ownership, the sales could be interpreted as a move for liquidity or portfolio rebalancing. Without further context on the reasons for these transactions or broader company performance, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions while monitoring future developments.

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Form 4, Insider Trading, Beneficial Ownership, Stock Transactions, Preferred Stock Conversion, Common Stock Sales, Director Transactions